Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.

Highly specialized infusion medicine is “a challenging environment” for all companies “and Coram has not been immune to these challenges,” the CVS release said. “As such, we have ...

The global home infusion therapy devices market is on the brink of remarkable expansion, projected to grow from USD 2.3 billion in 2023 to an estimated USD 4.4 billion by 2033, representing a compound ...

Sticky plaques building up on the walls of your blood vessels can lead to heart attacks and strokes. Now, a new nanoparticle ...

Antelope Valley Medical Center, in partnership with CarepathRx have announced the opening of an integrated, comprehensive ...

CareFusion, a BD subsidiary, is conducting layoffs as well as moving some of its engineering and manufacturing jobs to other ...

CVS Health plans to exit its core infusion services business in the coming months, according to Reuters. The company also ...

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...

While the makeup of the Franchise Times Top 400 Health & Medical category is changing, with regenerative therapy, mental ...

BoulderCentre for Orthopedics PC is suing the company that built its Broomfield clinic, claiming that Windsor-based Infusion ...

AbbVie Inc. said Thursday the Food and Drug Administration has approved its vyalev as the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of ...